The study, conducted at DaVita Clinical Research clinics, is aimed at further characterizing changes in the device’s patented Relative Index during hemodialysis procedures where a large volume of fluid is removed from patients.

“Given the current opioid epidemic and ongoing pain management crisis, we believe there is a need to better explore solutions that effectively address pain and support the elimination of oral opioids,” said Anu Codaty, vice president and general manager, Interventional Pain within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “Based on the findings of this study, there may be an added benefit for this patient population in reducing opioid-based harms.”

“This study shows promise around the potential to enhance patient safety by using machine learning platforms to build and maintain smart infusion drug libraries that dynamically review infusions and signal possible infusion errors,” said Douglas M. Hansell, M.D., MPH, vice president of medical affairs for Baxter’s Medication Delivery business.

First-in-Kind COVID-19 Decompensation Index (CDI) identifies early signs of worsening health with a lower false alarm rate compared to standard-of-care modalities.
Findings suggests the potential for wearable sensor-based analytics to detect exacerbation of infectious disease.